This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Enzo Biochem Reports Fourth Quarter And Fiscal Year Results

Enzo Biochem Inc. (NYSE:ENZ) today reported results for the fiscal fourth quarter and year ended July 31, 2013. On a sequential basis, as compared to the preceding third quarter, unless otherwise indicated, Enzo reported:
  • Total revenues increased 3% to $23.3 million.
  • Gross margins rose 4%, to $9.4 million, and gross profit, as a percentage of revenues, increased to 41%, from 40%.
  • Total operating expenses, net of legal and impairment charges, decreased by more than $7 million year over year, a decline of more than 12%.
  • Operating loss improved from the sequential quarter by $2.2 million and $0.9 million a year ago, net of impairment charges.
  • Net loss improved by 46% to ($3.1) million.
  • Cash used in operations was $1.5 million, an improvement of 62%.

“Much of what we have accomplished in Fiscal 2013 has been geared towards positioning Enzo Biochem towards capitalizing on its strong intellectual property portfolio through commercialization of diagnostic technology and products based on proprietary platforms such as AmpiProbe™” said Barry Weiner, President of Enzo. “We have continued to strengthen our translational diagnostic capabilities, increase the menu of both products and services in the high-value molecular and esoteric testing space and have concentrated the Company’s efforts around serving the diagnostic marketplace with high performing, cost effective products that are keys in today’s challenging healthcare environment.”

“We believe the value of this intellectual property was demonstrated by the jury award of $48.5 million, prior to any interest and damages award, through the favorable verdict Enzo received in the Life Technologies case, and hopefully will be shown in the upcoming litigation in New York Federal District Court.”

“Despite continued weakness in the academic and pharmaceutical-based research and development markets, our program at Life Sciences to improve efficiencies and emphasize higher margin product sales is paying off. Clinical Labs continues to add new diagnostic procedures while also improving collection efficiencies, as reflected in a 35% quarter over quarter improvement in the provision for uncollectible receivables. The vagaries of the insured healthcare market remain in flux, as reimbursements both via Medicare and among private insurers tightened. Our strategy, in addition to improving productivity and reducing overhead, has been to move increasingly to higher end esoteric diagnostics through both collaboration and in-house developments, a strategy that is reflected in the unit’s positive cash flow in the fourth quarter.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.00 -0.66%
FB $118.19 0.11%
GOOG $698.78 0.44%
YHOO $37.03 2.90%
TSLA $213.13 -4.20%


Chart of I:DJI
DOW 17,691.94 +40.68 0.23%
S&P 500 2,055.03 +3.91 0.19%
NASDAQ 4,734.1640 +8.5250 0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs